FDA Approves New Drug for Advanced Bladder Cancer

May 5, 2017

On Monday, May 1st, the FDA approved Imfinzi™ (durvalumab).  Imfinzi is manufactured by AstraZeneca, and it is a PD-L1 inhibitor indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma.  The immune-oncology drug is intended for use in patients “who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.”

In addition to the approval of Imfinzi, the FDA also approved the VENTANA PD-L1 (SP263) Assay. The product is manufactured by Ventana Medical Systems, Inc., and was approved “as a complementary diagnostic for the assessment of the PD-L1 protein in formalin-fixed, paraffin-embedded urothelial carcinoma tissue.”

According to the FDA’s announcement, Imfinzi’s “approval was based on one single-arm trial of 182 patients with locally advanced or metastatic urothelial carcinoma whose disease progressed after prior platinum-containing chemotherapy. Durvalumab, 10 mg/kg intravenously, was administered every 2 weeks. Confirmed objective response rate (ORR) as assessed by blinded independent central review per RECIST 1.1, was 17.0% (95% CI: 11.9, 23.3). At the data cutoff for the ORR analysis, median response duration was not reached (range: 0.9+ to 19.9+ months). ORR was also analyzed by PD-L1 expression status as measured by VENTANA PD-L1 (SP263) Assay. In the 182 patients, the confirmed ORR was 26.3% (95% CI: 17.8, 36.4) in 95 patients with a high PD-L1 score and 4.1% (95% CI: 0.9, 11.5) in 73 patients with a low or negative PD-L1 score.”

The most common adverse reactions experienced by patients while taking Imfinzi include:

  • Fatigue
  • Musculoskeletal pain
  • Constipation
  • Decreased appetite
  • Nausea
  • Peripheral edema
  • Urinary tract infection

Additionally, 43% of patients experienced Grade 3-4 adverse events, including infection and immune-related adverse events such as pneumonitis, hepatitis, colitis, thyroid disease, adrenal insufficiency, and diabetes.

The application, which was granted accelerated approval, priority review, and Breakthrough Therapy Designation, was approved six weeks prior to the FDA’s goal date.  In its announcement, FDA states that “as a condition of the accelerated approval, AstraZeneca is required to complete an ongoing clinical trial to confirm clinical benefit of durvalumab.”

For additional information on Imfinzi’s approval, view FDA’s announcement.

Do you have a product that you think may be eligible for FDA’s priority review program? We can help you determine if your product meets the necessary criteria and obtain FDA approval. To learn more about our services, contact us today.

Agency Alerts Regulatory Sciences

February 2, 2016

FDA & NIH Join Forces to Publish BEST Resource: a Glossary of Clinical Definitions

On January 28, 2016, an FDA and NIH Joint Leadership Council published its first official glossary of terms and definitions, which “clarifies important definitions and describes some of the...

Read the Full Article
Agency Alerts

May 25, 2016

FDA Warns of Possible Amputation Risk Associated with Diabetes Drug

On Wednesday, May 18th, FDA issued a Drug Safety Communication alerting the public of potential risks associated with canagliflozin (Invokana, Invokamet), which is used for the treatment of type 2...

Read the Full Article
Agency Alerts General Regulatory

July 8, 2016

Federal Circuit Court Requires Biosimilar Makers Participate in “Patent Dance” & Give 180-Day Notice

On Tuesday, July 5th the Federal Circuit Court announced the final decision in the case of Amgen v. Apotex, ruling that manufacturers of biosimilar products must notify their brand-name competitors...

Read the Full Article